Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiomericaBMRA -6.28%50 Days Payable is 0.00 as of Feb. 2026. GuruFocus rates BMRA with a GF Score™ of 50/100 and a GF Value™ of $2.18 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 794 Medical Devices & Instruments companies, Biomerica ranks worse than 88.79% on this metric.
Biomerica's average Accounts Payable for the
three
months ended in Feb. 2026 was $0.00 Mil. Biomerica's Cost of Goods Sold for the
three
months ended in Feb. 2026 was $1.03 Mil.
Hence, Biomerica's Days Payable for the
three
months ended in Feb. 2026 was 0.00.
The historical rank and industry rank for Biomerica's Days Payable or its related term are showing as below:
BMRA'
s Days Payable Range Over the Past 10 Years
Min: 13.4 Med: 34.41 Max: 77.31
Current: 26.01
During the past 13 years, Biomerica's highest Days Payable was 77.31. The lowest was 13.40. And the median was 34.41.
BMRA's Days Payable is ranked worse than 88.79% of 794
companies
in the Medical Devices & Instruments industry
Industry Median: 67.97
vs BMRA: 26.01
Biomerica's Days Payable
stayed the same
from Feb. 2025 (0.00) to Feb. 2026 (0.00).
stayed the same
The historical data trend for Biomerica's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Biomerica's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomerica Days Payable vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biomerica's Days Payable distribution charts can be found below:
* The bar in red indicates where Biomerica's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Biomerica's Days Payable for the fiscal year that ended in May. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomerica (BMRA) has a Days Payable of 0.00 as of Feb. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biomerica and its competitors. Over the past decade, Biomerica's Days Payable has ranged from 13.40 to 77.31. According to the industry distribution chart, Biomerica ranks #705 out of 794 companies in the Medical Devices & Instruments industry, placing it in the top 88.8%.
Is Biomerica's Days Payable too high?
Biomerica's current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 13.40 to a high of 77.31. Based on the distribution chart, Biomerica ranks #705 out of 794 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Biomerica has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biomerica's Days Payable compare to WOK and ALURD?
According to the Medical Devices & Instruments industry distribution chart, Biomerica ranks #705 out of 794 companies for Days Payable. This places Biomerica in the lower half of its industry. The industry median Days Payable is 67.97. Historically, Biomerica's own Days Payable has ranged from 13.40 to 77.31 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Devices & Instruments company?
The median Days Payable among Medical Devices & Instruments companies is 67.97, based on 794 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Biomerica and its competitors. For the Medical Devices & Instruments industry, the median Days Payable is 67.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomerica's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomerica stock overvalued right now?
Based on GuruFocus' analysis, Biomerica (BMRA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.18, compared to a current price of $1.49 — trading 31.7% below its estimated fair value. The current Days Payable is 0.00. Biomerica's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Biomerica (BMRA), the current Days Payable is 0.00 as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biomerica (BMRA) Overvalued in 2026?
Based on GuruFocus' analysis, Biomerica stock appears to be undervalued.
The current stock price of $1.49 is trading 31.7% below its estimated GF Value™ of $2.18.
GuruFocus considers Biomerica to be Possible Value Trap.
Key valuation signals for BMRA:
Days Payable: 0.00
GF Value™: $2.18 vs. price of $1.49 (31.7% below fair value)
No single metric tells the full story. See the BMRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.
50GF Score
Get the complete analysis for BMRA
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BMRA has been successfully added to your 
